TOPROL-XL
Clinical safety rating
cautionComprehensive clinical and safety monograph for TOPROL-XL (TOPROL-XL).
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
| Metabolism | Primarily metabolized by CYP2D6; minor pathways include dealkylation and glucuronidation. |
| Excretion | Metoprolol is extensively metabolized in the liver via CYP2D6; less than 5% of an oral dose is excreted unchanged in urine. The metabolites, primarily α-hydroxymetoprolol, are excreted renally. Biliary/fecal excretion accounts for less than 5% of the dose. |
| Half-life | Terminal elimination half-life is 3-7 hours, but in CYP2D6 poor metabolizers (about 7% of Caucasians) it can extend up to 8-10 hours. This variability is clinically relevant for dose titration. |
| Protein binding | Approximately 12% bound to plasma proteins (mainly albumin). This low binding is clinically insignificant for drug interactions. |
| Volume of Distribution | Volume of distribution is 4-5 L/kg, indicating extensive extravascular distribution. This is consistent with its lipophilic nature and ability to cross the blood-brain barrier. |
| Bioavailability | After oral administration, bioavailability is approximately 50% due to extensive first-pass hepatic metabolism. The extended-release formulation (TOPROL-XL) has similar bioavailability but provides more sustained plasma concentrations. |
| Onset of Action | Oral: 1 hour for reduction of exercise-induced tachycardia; maximal effect on heart rate occurs within 2-8 hours depending on dose and formulation (extended-release TOPROL-XL). Intravenous: immediate (5-10 minutes). |
| Duration of Action | After oral administration of extended-release formulation, the effect on heart rate and blood pressure lasts approximately 24 hours. Immediate-release tablets require twice-daily dosing. Duration may be longer in CYP2D6 poor metabolizers. |
| Molecular Weight | 267.4 |
100 to 400 mg orally once daily starting at 100 mg/day; maximum 400 mg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for GFR >10 mL/min; for GFR <10 mL/min, reduce dose by 50% or use alternative. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce initial dose by 50% and titrate cautiously; Child-Pugh Class C: avoid use or use extreme caution with 50% dose reduction. |
| Pediatric use | Not FDA-approved for pediatric patients; limited data suggest initial 1 mg/kg/day orally once daily, maximum 2 mg/kg/day or 200 mg/day. |
| Geriatric use | Initiate at lower doses (25-50 mg orally once daily) and titrate slowly; monitor heart rate and blood pressure closely. |
| 1st trimester | Metoprolol succinate is not recommended in the first trimester unless clearly needed. Studies suggest a potential risk of fetal bradycardia and low birth weight. Use only if benefit outweighs risk. |
| 2nd trimester | Use with caution in the second trimester. Monitor fetal growth and heart rate. May cause fetal bradycardia and growth restriction. |
| 3rd trimester | Avoid in the third trimester due to risk of neonatal bradycardia, hypotension, and hypoglycemia. If used, monitor neonate closely after delivery. |
Clinical note
Comprehensive clinical and safety monograph for TOPROL-XL (TOPROL-XL).
| Placental transfer | Metoprolol crosses the placenta. Studies report fetal/maternal concentration ratios of 0.5-1.1. It is extensively distributed and can accumulate in fetal tissues. |
| Breastfeeding | Metoprolol is excreted into breast milk in small amounts (relative infant dose approximately 0.5-0.8% of maternal weight-adjusted dose). No adverse effects have been reported in breastfed infants. Use with caution in infants with impaired cardiac function or bradycardia. Monitor infant for signs of beta-blockade. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no major malformations at clinically relevant doses. Second and third trimesters: Associated with fetal bradycardia, intrauterine growth restriction, and neonatal hypoglycemia due to beta-blockade. Risk of preterm labor may be increased. |
| Fetal Monitoring | Maternal: Blood pressure, heart rate, and signs of heart failure or bronchospasm. Fetal/Neonatal: Fetal heart rate monitoring during labor; neonatal assessment for bradycardia, hypoglycemia, and respiratory depression after delivery. |
| Fertility Effects | No specific human studies on fertility; animal studies show no impairment. Beta-blockers may rarely cause sexual dysfunction, but impact on fertility is unlikely. |
■ FDA Black Box Warning
Do not abruptly discontinue; taper dose over 1-2 weeks to avoid exacerbation of angina, MI, or ventricular arrhythmias.
| Serious Effects |
Sinus bradycardiaHeart block greater than first degreeCardiogenic shockDecompensated cardiac failureSick sinus syndrome (unless pacemaker in place)Severe peripheral arterial diseaseHypersensitivity to metoprolol or any component of the formulationBronchial asthma (avoid, especially non-cardioselective doses)
| Precautions | Exacerbation of angina and MI upon abrupt withdrawal, Heart failure (may worsen; monitor for signs of fluid retention), Bradycardia and heart block, Bronchospasm in patients with asthma/COPD (use with caution), Peripheral vascular disease (may aggravate symptoms), Thyrotoxicosis (may mask tachycardia), Diabetes (may mask hypoglycemia symptoms), Renal impairment (dose adjustment may be needed) |
| Food/Dietary | No specific food interactions. However, avoid excessive alcohol as it may potentiate hypotension and dizziness. |
| Clinical Pearls | TOPROL-XL (metoprolol succinate) is a beta-1 selective adrenergic blocker. Use with caution in asthma/COPD due to potential bronchospasm. Do not abruptly discontinue; taper over 1-2 weeks to avoid rebound hypertension or ischemia. Monitor heart rate and blood pressure; target heart rate 55-65 bpm for stable angina or heart failure. In heart failure, start low (12.5-25 mg daily) and titrate slowly every 2 weeks. Avoid in decompensated heart failure. May mask signs of hypoglycemia. |
| Patient Advice | Take exactly as prescribed, usually once daily, with or without food. · Do not stop taking without consulting your doctor; sudden discontinuation can cause chest pain or heart attack. · Monitor for slow heart rate, dizziness, or fainting; report these to your doctor. · If you have diabetes, check blood sugar regularly as this drug may mask hypoglycemia symptoms. · Avoid alcohol as it may increase side effects like dizziness. |
Loading safety data…